Mostaghel et al. have shown that the blockade of androgen receptor in mantle cell lymphoma with antiandrogen enzalutamide suppresses cell proliferation in vitro.[27] Our results indicated a higher occurrence of hematologic malignancy with the use of GnRH agonists and oral antiandrogens. Here, AR is linked to hematologic disorder.